SynthesisScientific reports2017
Relationship between initiation time of adjuvant chemotherapy and survival in ovarian cancer patients: a dose-response meta-analysis of cohort studies.
Synthesis in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Guideline
- Association between antidepressant medication use and epithelial ovarian cancer risk: a systematic review and meta-analysis of observational studies.British journal of clinical pharmacology · 2018Pooled it
- Effect of intraperitoneal ropivacaine during and after cytoreductive surgery on time-interval to adjuvant chemotherapy in advanced ovarian cancer: a randomised, double-blind phase III trial.British journal of anaesthesia · 2025Trial
- Predictors of postoperative morbidity and delayed initiation of adjuvant chemotherapy after cytoreductive surgery in advanced-stage epithelial ovarian cancer.World journal of surgical oncology · 2026Article
- A Meta-Analysis on the Long-Term Impact of Cytoreductive Surgery Plus HIPEC for Ovarian Cancer with Peritoneal Metastasis: Are We on the Right Path?Life (Basel, Switzerland) · 2026Review
- Parameter efficient fine-tunning of foundation model to facilitate tumor response prediction for ovarian cancer patients.BMC medical imaging · 2025Article
- Earlier is not always better: Optimal time to initiate adjuvant chemotherapy after surgery for ovarian cancer.Archives of gynecology and obstetrics · 2025Article
- Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Clinical Insights.JCO oncology practice · 2025Article
- Inclusion in the cancer patient pathway among cancer patients with and without pre-existing mental or substance use disorders: a nationwide register-based study.BMC public health · 2025Article
- Association between time to adjuvant chemotherapy and survival in ovarian cancer patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.Gynecologic oncology reports · 2025Article
- Radical Oophorectomy for Advanced Ovarian Cancer: A Feasibility Study from Tertiary Care Cancer Centre in Eastern India.Journal of obstetrics and gynaecology of India · 2024Article
- Effect of different treatment modalities on ovarian cancer patients with liver metastases: A retrospective cohort study based on SEER.PloS one · 2024Article
- Phase II Trial on the Feasibility of Single-Dose Intraoperative Intraperitoneal Carboplatin in Advanced Epithelial Ovarian Cancer Following Optimal Cytoreductive Surgery.Indian journal of surgical oncology · 2023Article
- Article
- Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients.Frontiers in oncology · 2023Article
- Prognostic influence of an early time to chemotherapy following primary cytoreductive surgery for advanced epithelial ovarian cancer.Journal of gynecologic oncology · 2022Article
- The impact of interval between primary cytoreductive surgery with bowel resection and initiation of adjuvant chemotherapy on survival of women with advanced ovarian cancer: a multicenter cohort study.Journal of gynecologic oncology · 2022Article
- Article
- Novel evolutionary dynamics of small populations in breast cancer adjuvant and neoadjuvant therapy.NPJ breast cancer · 2021Review
- The implementation of enhanced recovery after surgery protocols in ovarian malignancy surgery.Gland surgery · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Although several studies have previously investigated the association between the initiation time of adjuvant chemotherapy and survival in ovarian cancer, inconsistencies remain about the issue. We searched PubMed and Web of Science through the May 24, 2017 to identify cohort studies that investigated the aforementioned topic. Fourteen studies with 59,569 ovarian cancer patients were included in this meta-analysis. We conducted meta-analyses comparing the longest and shortest initiation time of adjuvant chemotherapy and dose-response analyses to estimate summary hazards ratios (HRs) and 95% confidence intervals (CIs). A random-effects model was used to estimate HRs with 95% CIs. When comparing the longest with the shortest category of initiation time of adjuvant chemotherapy, the summary HR was 1.18 (95% CI: 1.06-1.32; I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.